Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials
Top Cited Papers
Open Access
- 25 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10), e47559
- https://doi.org/10.1371/journal.pone.0047559
Abstract
Mesenchymal stromal cells (MSCs, “adult stem cells”) have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously or intra-arterially) in adult populations or mixed adult and pediatric populations were identified. Studies using differentiated MSCs or additional cell types were excluded. The primary outcome adverse events were grouped according to immediate events (acute infusional toxicity, fever), organ system complications, infection, and longer term adverse events (death, malignancy). 2347 citations were reviewed and 36 studies met inclusion criteria. A total of 1012 participants with clinical conditions of ischemic stroke, Crohn's disease, cardiomyopathy, myocardial infarction, graft versus host disease, and healthy volunteers were included. Eight studies were randomized control trials (RCTs) and enrolled 321 participants. Meta-analysis of the RCTs did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. There was a significant association between MSCs and transient fever. Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.Keywords
This publication has 55 references indexed in Scilit:
- Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in strokeBrain, 2011
- A Novel Approach to Transplanting Bone Marrow Stem Cells to Repair Human Myocardial Infarction: Delivery via a Noninfarct‐relative ArteryCardiovascular Therapeutics, 2010
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Mesenchymal stem cells for acute lung injury: Preclinical evidenceCritical Care Medicine, 2010
- Mesenchymal stem cell as salvage treatment for refractory chronic GVHDBone Marrow Transplantation, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2009
- Infusion of Mesenchymal Stromal Cells can Aid Hematopoietic Recovery Following Allogeneic Hematopoietic Stem Cell Myeloablative Transplant: A Pilot StudyStem Cells and Development, 2009
- Mesenchymal Stem Cell Transplantation Reverses Multiorgan Dysfunction in Systemic Lupus Erythematosus Mice and HumansThe International Journal of Cell Cloning, 2009
- Prevention of LPS-Induced Acute Lung Injury in Mice by Mesenchymal Stem Cells Overexpressing Angiopoietin 1PLoS Medicine, 2007
- HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cellsExperimental Hematology, 2003